FDA Watch: A New Blood Test for Accurate Alzheimer’s Detection
The ALZpath DX assay is less invasive than other diagnostic tests, and may give patients diagnosed with Alzheimer’s more time to plan
Keeps You Up-to-Date on New Diagnostic Tests, Testing Trends and Opportunities, and Emerging Test Technologies
The ALZpath DX assay is less invasive than other diagnostic tests, and may give patients diagnosed with Alzheimer’s more time to plan
Approval for OTC use of a urine drug test that can be performed by non-CLIA facilities could help expand accessibility, expert says.
Patients’ unfettered access to complex test results can lead to confusion and distress—but generative AI can help.
Crystal Girod, MSc, of Beckman Coulter Life Sciences discusses recent developments in NGS and their impact on clinical diagnostics.
Debate is underway on whether current CLIA review of LDTs properly assesses a test’s likelihood to detect diseases.
Juan Antonio Retamero, MD, shares his thoughts on recent trends in AI and digital pathology, and how they may progress.
The changes proposed in three new draft guidances aim to speed up the process and place less emphasis on older predicate products.
Liron Pantanowitz, MD, PhD, discusses the key issues pathologists face today, and how technology could help.
Artificial intelligence won’t take your job—but what are the real concerns around healthcare AI and its use?
AI is an increasingly useful tool in pathology—but its full value can only be realized in collaboration with human experts.
Diana W. Bianchi, MD, discusses how NIPT has evolved, key challenges, as well as her team’s research on using these tests to detect cancer.